Oncolytics Biotech News and Activities

Oncolytics Biotech is a company listed under the stock ticker ONC (CA).

View the org chart displaying its 22 main executives

Most searched biographies at Oncolytics Biotech

• Jared Kelly, Chief Executive Officer and Director
• James Parsons, Director
• Bernd Seizinger, Director

Popular executive movements at Oncolytics Biotech

• John Mcadory, who was Executive Vice President of Strategy and Operations, is promoted to Chief Operating Officer  (posted on June 2 2026).
• Steve Glover has joined the company as Director  (posted on June 2 2026).
• Yujun Wu has joined the company as Vice President, Head of Biostatistics  (posted on January 14 2026).

Click here to view some more movements at Oncolytics Biotech

Create your alert
to follow the executive moves at Oncolytics Biotech.

Oncolytics Biotech has 2,406 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
• NewLimit has just announced a $435 Million fundraising (posted on June 3 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Valerie Hanote - Non-Executive Director at Eurofins

Learn more about the Biotechnology industry

Press releases by Oncolytics Biotech

• Regulatory Approval Clears Path for Oncolytics Biotech® to Advance Promising Pancreatic Cancer Treatment, Following a Review of Safety Data | Oncolytics Biotech Inc.
• Oncolytics Biotech® Highlights 2024 Achievements and Prepares for an Influential 2025 with Promising Breast and GI Cancer Data | Oncolytics Biotech Inc.
• Oncolytics Biotech® to Present Promising Pelareorep Data in Pancreatic and Anal Cancers at ASCO GI Symposium | Oncolytics Biotech Inc.
• Oncolytics Biotech® Reports Completion of Initial Safety Phase Enrollment for GOBLET Trial's New Pancreatic Cancer Cohort | Oncolytics Biotech Inc.
• Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights | Oncolytics Biotech Inc.
• Oncolytics Biotech® Reports Third Quarter 2024 Financial Results and Operational Highlights | Oncolytics Biotech Inc.
• Oncolytics Biotech® Announces Key Progress and Upcoming Studies for Breast and Pancreatic Cancer Treatments, Prepares for FDA Accelerated Approval Path | Oncolytics Biotech Inc.
• Oncolytics Biotech® Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study | Oncolytics Biotech Inc.
• Oncolytics Biotech® to Participate in Fireside Chats at Two Investment Conferences in September | Oncolytics Biotech Inc.
• Oncolytics Biotech® Reports Second Quarter 2024 Financial Results and Operational Highlights | Oncolytics Biotech Inc.
• View more press releases Close

Social media about Oncolytics Biotech

• Oncolytics Biotech on Wikipedia, Google News & Yahoo Finance
• Oncolytics Biotech on LinkedIn, X (Twitter) & YouTube